Project Grant R01CA302791
Award Date 6/26/26
Completion Date 5/31/29
Dollars Obligated $736K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $694,015 to the Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) for a five-year Project Grant beginning July 1, 2026, and concluding June 30, 2031. The award funds fundamental research focused on identifying and targeting cancer immune evasion mechanisms, specifically examining how tumor-associated macrophages (TAMs) recognize and eliminate cancer cells through a process...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $733,864 Project Grant to the Beckman Research Institute of the City of Hope, effective June 1, 2026 through May 31, 2031. The award funds fundamental research to identify and characterize stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR), a critical process in tumor immunosurveillance and cancer elimination. Using...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Beckman Research Institute of the City of Hope a $702,495 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2030. This research initiative focuses on developing novel therapeutic approaches to treat T cell lymphomas (TCLs), a highly heterogeneous group of lymphoid malignancies representing approximately 12% of all non-Hodgkin lymphomas. The project...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Project Grant Award Summary The Beckman Research Institute of The City Of Hope received a $457,683 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026, through May 31, 2028. This award supports fundamental and applied laboratory research investigating the mechanisms of ibrutinib resistance in mantle cell lymphoma (MCL), an incurable B-cell malignancy. The research focuses on understanding how MCL tumors...
- Federal Grant Award Summary The National Cancer Institute awarded $435,788 to the University of Pittsburgh under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, for a five-year project concluding March 31, 2031. The grant supports the development of active site-directed inhibitors and bifunctional degraders (PROTACs—proteolysis-targeting chimeras) targeting mutant isocitrate dehydrogenase (IDH1 and IDH2) enzymes implicated in gliomas and hematological malignancies. The...
- Federal Grant Award Summary The National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded a $661,721 Project Grant to the University of California, San Diego, effective April 1, 2026, through March 31, 2031. This award supports systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The research will utilize high-throughput functional screening technologies to perform domain and residue-level...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell immunogenicity in glioblastoma. The project, which extends through May 31, 2029, will expose glioblastoma neurosphere models to 3,792 small molecules targeting diverse cellular activities and...